+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Dobutamine stress echocardiography in the evaluation of late anthracycline cardiotoxicity in childhood cancer survivors



Dobutamine stress echocardiography in the evaluation of late anthracycline cardiotoxicity in childhood cancer survivors



Pediatric Research 39(3): 504-512



Late anthracycline cardiotoxicity has been of increasing concern to pediatric oncologists. An increasing number of patients with cardiac dysfunction has been reported without a good correlation between cardiac function or symptoms and routine echocardiographic follow-up. We studied dobutamine stress echocardiography in patients who had received moderate doses of anthracyclines years before. Twenty-three patients (14 male, 9 female; 7-25 y) who completed chemotherapy with moderate doses of anthracyclines (180-380 mg/m2) more than 2 y previously underwent dobutamine stress echocardiography and were compared with a control group of 26 healthy young people (15 male, 11 female; 6-26 y) matched for age and weight. Dobutamine was administered in three periods up to a rate of 5 micro g/kg/min. Eighty-five percent of the patients showed an abnormal response to dobutamine. Both systolic and diastolic functions were affected. The systolic dysfunction was not related to diminished contractility but to an elevated systolic wall stress due to inadequate cardiac muscle thickening. The diminished wall thickening was related to the length of follow-up. Dobutamine proved to be a very sensitive method to detect clinical and subclinical cardiac dysfunction in patients post anthracycline chemotherapy and questions the concept of a safe dose.

(PDF emailed within 1 workday: $29.90)

Accession: 008496528

Download citation: RISBibTeXText

PMID: 8929873


Related references

Detection of early anthracycline-induced cardiotoxicity in childhood cancer with dobutamine stress echocardiography. Turkish Journal of Pediatrics 40(3): 373-383, 1998

Evaluation of cardiac reserved function by high-dose dobutamine-stress echocardiography in asymptomatic anthracycline-treated survivors of childhood cancer. Pediatrics International 48(3): 313-320, 2006

The use of metabolic stress testing and exercise stress echocardiography in pediatric cancer survivors to detect early stages of late-onset anthracycline induced cardiotoxicity. Journal of Investigative Medicine 48(5): 235A, 2000

Are cardiac magnetic resonance imaging and radionuclide ventriculography good options against echocardiography for evaluation of anthracycline induced chronic cardiotoxicity in childhood cancer survivors?. Pediatric Hematology and Oncology 31(3): 237-252, 2015

Tissue and flow myocardial performance index measurements taken during dobutamine stress echocardiography for early diagnosis of late anthracycline cardiotoxicity. Pediatric Cardiology 31(1): 96-105, 2010

Low-dose dobutamine echo stress test for the evaluation of cardiac function in asymptomatic childhood cancer survivors treated years before with anthracycline. European Heart Journal 19(ABST SUPPL ): 312, 1998

Dobutamine stress echocardiography identifies anthracycline cardiotoxicity. European Journal of Echocardiography 1(3): 180-183, 2002

Utility of Echocardiography as Screening for Late-onset Anthracycline-induced Cardiotoxicity in Pediatric Cancer Survivors: Observations from the First Decade After End of Therapy. Journal of Pediatric Hematology/Oncology 40(5): E283-E288, 2018

Subclinical anthracycline-induced cardiotoxicity in long-term follow-up of asymptomatic childhood cancer survivors: Assessment by speckle tracking echocardiography. Echocardiography 35(2): 234-240, 2017

Repetitive dobutamine stress echocardiography for the prediction of anthracycline cardiotoxicity. European Journal of Echocardiography 4(4): 300-305, 2003

Evaluation of traditional and novel measures of cardiac function to detect anthracycline-induced cardiotoxicity in survivors of childhood cancer. Journal of Cancer Survivorship 8(2): 183-189, 2015

Assessing anthracycline-treated childhood cancer survivors with advanced stress echocardiography. Pediatric Blood and Cancer 62(3): 502-508, 2015

Cranial irradiation as an additional risk factor for anthracycline cardiotoxicity in childhood cancer survivors: an analysis from the cardiac risk factors in childhood cancer survivors study. Pediatric Cardiology 34(4): 826-834, 2013

Anthracycline-associated cardiotoxicity in survivors of childhood cancer. Pediatric Cardiology 32(3): 342-353, 2011

Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 94(4): 525-533, 2008